IP receptor (prostacyclin pathway)

Assets acting on this target.

Class
Prostacyclin pathway agonist

The IP receptor is a G protein–coupled receptor found mainly on vascular smooth muscle cells and platelets. Its natural ligand, prostacyclin (prostaglandin I2), is produced by the endothelium lining blood vessels and acts locally to relax smooth muscle, widen blood vessels, and reduce platelet clumping. In pulmonary arterial hypertension, the vessels supplying the lungs undergo abnormal narrowing and remodeling, and endogenous prostacyclin signaling is often reduced. Restoring this signaling through IP receptor agonism lowers vascular resistance, improves blood flow through the lungs, and may slow the vessel-wall changes that drive disease progression. Because natural prostacyclin degrades within minutes in the bloodstream, therapeutic strategies rely either on stable synthetic analogs of the molecule or on small molecules designed to bind the receptor directly with a longer duration of action. These agents can be delivered intravenously, by inhalation, or orally, with the route influencing how much drug reaches the lungs versus the rest of the circulation. This mechanism broadly matters in pulmonary hypertension and related vascular disorders where insufficient vasodilatory signaling contributes to elevated pressure and impaired blood flow.

By indication

IP receptor (prostacyclin pathway) drugs compared

8 drugs, stage by indication
8 drugs acting on IP receptor (prostacyclin pathway): developer, modality, furthest stage and stage in each indication. Furthest stage first.
DrugDeveloperModalityFurthest stageStage by indication
EpoprostenolFlolanGlaxoSmithKlinesmall molecule (prostacyclin)ApprovedApproved in Pulmonary Arterial Hypertension
Treprostinil (Orenitram)OrenitramUnited Therapeuticssmall moleculeApprovedApproved in Pulmonary Arterial Hypertension
Treprostinil (Remodulin)RemodulinUnited Therapeuticssmall moleculeApprovedApproved in Pulmonary Arterial Hypertension
Treprostinil (Tyvaso DPI)Tyvaso DPIMannKind Corporation, United Therapeuticssmall moleculeApprovedApproved in Pulmonary Arterial Hypertension; Approved in Pulmonary Hypertension Associated with Interstitial Lung Disease
Treprostinil (Tyvaso)TyvasoUnited Therapeuticssmall moleculeApprovedApproved in Pulmonary Arterial Hypertension; Approved in Pulmonary Hypertension Associated with Interstitial Lung Disease; Phase 3 in Idiopathic Pulmonary Fibrosis
Treprostinil (Yutrepia, Liquidia)YutrepiaLiquidia Corporationsmall molecule (prostacyclin analogue, inhaled dry powder)ApprovedApproved in Pulmonary Arterial Hypertension; Approved in Pulmonary Hypertension Associated with Interstitial Lung Disease; Phase 2 in Systemic Sclerosis
RalinepagUnited Therapeuticssmall moleculePhase 3Phase 3 in Pulmonary Arterial Hypertension
Treprostinil (L606)Liquidia Corporation, Pharmosa Biopharm Inc.small molecule (prostacyclin analogue, inhaled liposomal)Phase 3Phase 3 in Pulmonary Arterial Hypertension; Phase 3 in Pulmonary Hypertension Associated with Interstitial Lung Disease

← all mechanisms